Ahmedabad: ChrysCapital affiliate, Sepia Investments-backed Corona Remedies Limited has filed its Draft Red Herring Prospectus (“DRHP”) with market regulator Securities and Exchange Board of India (“SEBI”).

The company is engaged in developing, manufacturing and marketing products in women’s healthcare, cardio-diabeto, pain management, urology and other therapeutic areas and it plans to raise funds through initial public offerings (IPO) aggregating up to ₹800 Crore. The entire ₹800 Crore is an Offer For Sale.

The Equity Shares are proposed to be listed on the BSE Limited (“BSE”) and National Stock Exchange of India Limited (“NSE”).

JM Financial Limited, IIFL Capital Services Limited (formerly known as IIFL Securities Limited) & Kotak Mahindra Capital Company Limited are the Book Running Lead Managers to the issue.

Corona Remedies Ltd is an India-focused branded pharmaceutical formulation company engaged in developing, manufacturing and marketing products in women’s healthcare, cardio-diabeto, pain management, urology and other therapeutic areas. According to the CRISIL Report, the company is second fastest growing company among the top 30 companies in the Indian Pharmaceutical Market (“IPM”) in terms of domestic sales between MAT December 2021 and MAT December 2024 (MAT = Moving Annual Total)

The company’s diversified product portfolio comprises 67 brands catering to a range of therapeutic areas such as women’s healthcare, cardio-diabeto, pain management and urology, among others, as of December 31, 2024.DeshGujarat